You are here

Article info

Article menu
Immune cell therapies and immune cell engineering
Patient-reported outcomes in CD30-directed CAR-T cells against relapsed/refractory CD30+ lymphomas

Authors

  • Nicholas P Tschernia Medical Oncology Service, National Institutes of Health, Bethesda, Maryland, USA PubMed articlesGoogle scholar articles
  • Hillary Heiling Lineberger Comprehensive Cancer Center, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA PubMed articlesGoogle scholar articles
  • Allison M Deal Lineberger Comprehensive Cancer Center, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA PubMed articlesGoogle scholar articles
  • Catherine Cheng Lineberger Comprehensive Cancer Center, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA PubMed articlesGoogle scholar articles
  • Caroline Babinec Lineberger Comprehensive Cancer Center, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA PubMed articlesGoogle scholar articles
  • Megan Gonzalez Lineberger Comprehensive Cancer Center, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA PubMed articlesGoogle scholar articles
  • J Kaitlin Morrison Lineberger Comprehensive Cancer Center, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USADepartment of Medicine, The University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, North Carolina, USA PubMed articlesGoogle scholar articles
  • Christopher Dittus Lineberger Comprehensive Cancer Center, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USADepartment of Medicine, The University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, North Carolina, USA PubMed articlesGoogle scholar articles
  • Gianpietro Dotti Lineberger Comprehensive Cancer Center, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USADepartment of Microbiology and Immunology, The University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, North Carolina, USA PubMed articlesGoogle scholar articles
  • Anne W Beaven Lineberger Comprehensive Cancer Center, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USADepartment of Medicine, The University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, North Carolina, USA PubMed articlesGoogle scholar articles
  • Jonathan S Serody Lineberger Comprehensive Cancer Center, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USADepartment of Medicine, The University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, North Carolina, USA PubMed articlesGoogle scholar articles
  • William A Wood Lineberger Comprehensive Cancer Center, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USADepartment of Medicine, The University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, North Carolina, USA PubMed articlesGoogle scholar articles
  • Barbara Savoldo Lineberger Comprehensive Cancer Center, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USADepartment of Pediatrics, The University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, North Carolina, USA PubMed articlesGoogle scholar articles
  • Natalie S Grover Lineberger Comprehensive Cancer Center, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USADepartment of Medicine, The University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, North Carolina, USA PubMed articlesGoogle scholar articles
  1. Correspondence to Dr Natalie S Grover; natalie_grover{at}med.unc.edu
View Full Text

Citation

Tschernia NP, Heiling H, Deal AM, et al
Patient-reported outcomes in CD30-directed CAR-T cells against relapsed/refractory CD30+ lymphomas
Journal for ImmunoTherapy of Cancer 2023;11:e006959. doi: 10.1136/jitc-2023-006959

Publication history

  • Accepted July 12, 2023
  • First published August 1, 2023.
Online issue publication 
August 01, 2023

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.